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Case 1 
In April 2006, a 77-year-old female fractured her left femur 
after falling. The cortex had a spike-shaped edge at the frac-
ture site and also showed thickening (Figure 1). Intramedul-
lary nailing was performed. The fracture gap remained open 
1 year after surgery (Figure 2), but healing was confirmed by 
radiography 2 years after the injury. 2.5 years after the first 
injury, the patient fell while walking and contracted a diaphy-
seal transverse fracture of the right femur. The cortex had a 
spike-shaped edge at the fracture site. 
The patient had been given ethidronate (4.8 g/12 weeks) 
from January 1999 to October 2001 because of postmeno-
pausal osteoporosis. Thereafter, she was given alendronate (5 
mg/day) for 7 years until the right femoral fracture had healed. 
Urine  analysis  conducted  in  February  2004  showed  a  free 
deoxypyridinoline/creatinine ratio (f-DPD/Cre) of 3.1, which 
is at the lower end of the normal range (2.8–7.6).
Case 2
In May 2009, a 78-year-old female felt that she was going 
to fall while walking, and contracted a diaphyseal transverse 
fracture. The cortex had a spike shaped-edge at the fracture 
site (Figure 3). The lateral cortex of the contralateral femur 
was also thickened (Figure 4). This patient had been admin-
istered risedronate (2.5 mg/day) for 2 years, from November 
2002 until November 2004, because of postmenopausal osteo-
porosis.  Thereafter,  she  was  given  alendronate  (5  mg/day) 
until October 2008. In the next half-year period from October 
2008, she was administered raloxifene (60 mg/day). Her tar-
trate-resistant acid phosphatase 5b (TRACP-5b) 2 days after 
the injury was 111 mU/dL, which is below the standard values 
for postmenopausal females (250–260).
Case 3
In March 2004, a 70-year-old female fell and contracted a 
diaphyseal transverse fracture of her right femur with spike-
shaped cortical thickening laterally. The lateral cortex of the 
left femur was also thickened. Union was confirmed by radio-
graphs 6 months after intramedullary nailing. In September 
2004, she felt that she was falling and experienced pain in her 
left femur. Radiographs showed an incomplete fracture, and 
she was advised to rest and support her leg. She was able to 
walk again, putting weight on the leg in December. In March 
2005, she felt that she was about to fall and fractured the left 
femur. Again, the cortex presented a spike-shaped edge at the 
fracture. The patient had been administered risedronate (2.5 
mg/day) from June 2002 through January 2005.
Discussion
Suppression of bone resorption is the principal pharmacologi-
cal activity of bisphosphonates. Bisphosphonates are there-
fore widely used in the treatment of osteoporosis. They reduce 
the risk of fractures (Kwek et al. 2008). However, the pos-
sibility of severely suppressed bone turnover (SSBT) under 
long-term administration has been cited (Black et al. 2006). 
In other words, repair of the microdamage to bones in daily 
life is inhibited by bone resorption suppression agents, and 
the cumulative effect of this microdamage is the mechanism 
behind vulnerability of the bone (Mashiba et al. 2000). Some 
characteristics of meta/diaphyseal stress fractures include (1) 
that they result from light trauma, (2) that they are simple 
and transverse, (3) that one side of the bone cortex shows a 
spike-shaped edge, (4) that there is thickening of the lateral 
cortex (Odvina et al. 2010), (5) that there is delayed union, 
and (6) that there is presentation of symptoms before the frac-
ture (Ciarella et al. 2003). Points (1)–(4) were characteristics 
of all our cases. Furthermore, the fracture gap that persisted 
for a year in case 1 might be an example of (5). In addition, a 
reduction in bone resorption markers was confirmed in cases 
1 and 2.
Since the first case of a fatigue bone fracture during treat-
ment with alendronate, reported in 2005 by Odvina et al., 
there have been a number of such cases described in the litera-
ture (Black et al. 2006). Furthermore, there have been some 
rarer reports with risedronate (Ensrud et al. 2004, Goh et al. 
2007). To our knowledge, however, there have been no previ-
ous reports regarding raloxifene. Here, in case 2, we report 
a fatigue bone fracture after 6 years of bisphosphonate treat-
ment, followed by a switch to raloxifene. In case 3, a complete 
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administration. This is the only report of fatigue bone frac-
tures after transition from bisphosphonate to raloxifene treat-
ment or after suspension of risedronate administration.
Several cases of fatigue fractures of the femur in patients on 
long-term bisphosphonate treatment were reported by Aspen-
berg (2009). Almost half of the patients had bilateral fractures 
and a quarter of them took corticosteroids. On the other hand, 
Schilcher and Aspenberg (2009) reported that the incidence 
density  of  stress  fractures  associated  with  bisphosphonate 
use was low and acceptable, considering that bisphosphonate 
treatment is likely to reduce the incidence density of any frac-
ture. Black et al. (2010) concluded that the risk of fracture 
of the subtrochanteric or diaphyseal femur associated with 
bisphosphonate use was very low.
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Figure 1. Case 1. The right 
femur showed lateral corti-
cal thickening with a jagged 
pattern (arrow).
Figure 2. Case 1. Reduced frac-
ture gap of the left femur (arrow-
heads) 1 year postoperatively.
Figure 3. Case 2. Right trans-
verse  diaphyseal  fracture 
with a medial spike (arrow).
Figure 4. Case 2. The left femur showed cortical 
thickening with a jagged pattern (arrow).